Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Acaryon GmbH is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. BRANDSEN, BENJAMIN MICHAEL is identified as the busiest examiner, currently overseeing 1 pending action.
The presence of 2 pending office actions across 2 distinct art units suggests that the company's filings are being reviewed in multiple technical divisions within the Biotechnology & Pharmaceuticals sector. Since BRANDSEN, BENJAMIN MICHAEL is the busiest examiner with 1 pending action, the workload is distributed among the 2 distinct examiners. This structure requires coordination across different individuals to manage the portfolio's current patent applications.
Practitioners should observe that the use of 2 distinct examiners and 2 distinct art units necessitates a flexible approach to prosecution. Each examiner may have different requirements, even within the same technology area. The data reflects a portfolio that is interacting with multiple facets of the patent office's biotechnology divisions through these 2 distinct art units, rather than a single point of contact.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRANDSEN, BENJAMIN MICHAEL | 1 | 60.2% | +18.6% |
| DICKENS, AMELIA NICOLE | 1 | 47.6% | +21.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277535 | POLYSACCHARIDE COMPLEX | BRANDSEN, BENJAMIN MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17768138 | Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof | DICKENS, AMELIA NICOLE | 80d overdue |
| 18277535 | POLYSACCHARIDE COMPLEX | BRANDSEN, BENJAMIN MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18277535 | POLYSACCHARIDE COMPLEX | BRANDSEN, BENJAMIN MICHAEL | 1693 | §102§103§112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 17768138 | Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof | DICKENS, AMELIA NICOLE | 1645 | §112 | Final Rejection | 80d overdue | Pending | Apr 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial